Xenetic Biosciences’ (XBIO) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Xenetic Biosciences (NASDAQ:XBIO) in a research note issued to investors on Thursday morning,Benzinga reports. HC Wainwright also issued estimates for Xenetic Biosciences’ Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.84) EPS and Q4 2025 earnings at ($0.88) EPS.

Xenetic Biosciences Trading Down 0.9 %

Shares of NASDAQ XBIO opened at $3.37 on Thursday. The firm has a market cap of $5.20 million, a PE ratio of -1.27 and a beta of 2.17. Xenetic Biosciences has a 1-year low of $2.78 and a 1-year high of $5.20. The company has a fifty day moving average price of $3.98 and a 200 day moving average price of $3.99.

Xenetic Biosciences (NASDAQ:XBIO) last announced its earnings results on Tuesday, March 18th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48). The company had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.18 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. Equities research analysts forecast that Xenetic Biosciences will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation purchased a new position in shares of Xenetic Biosciences Inc (NASDAQ:XBIO) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned approximately 0.71% of Xenetic Biosciences at the end of the most recent reporting period. 15.12% of the stock is owned by institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.